Magnetar Financial’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Magnetar Financial’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-231,100	Closed	-$2.33M	–	891
2022 Q4	$2.33M	Hold	231,100	–	–	0.04%	382
2022 Q3	$2.29M	Buy	231,100 +132,163	+134%	+$1.3M	0.03%	549
2022 Q2	$968	Buy	98,937 +88,596	+857%	+$867K	0.01%	984
2022 Q1	$101K	Hold	10,341	–	–	﹤0.01%	1174
2021 Q4	$100K	Hold	10,341	–	–	﹤0.01%	1295
2021 Q3	$100K	Buy	+10,341	New	+$100K	﹤0.01%	1230

Magnetar Financial's EBAC Position: Q1 2023 in Review

Magnetar Financial sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 231,100 shares — an estimated $2.33M sold.

Magnetar Financial first reported a position in EBAC in Q3 2021 and held it in 6 quarters. The position peaked at $2.33M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Magnetar Financial reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Magnetar Financial sold 231,100 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $2.33M.
Magnetar Financial first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q3 2021 and held it in 6 quarters.
Magnetar Financial's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $2.33M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Magnetar Financial's 13F filing for Q1 2023, filed 15 May 2023.